Pfizer, Allergen Deal at Risk Over New Tax Rules

The video discusses the impact of Treasury's new rules on the Pfizer-Allergan deal, focusing on ownership structure and tax benefits. It explains earnings stripping and inversion strategies, and the implications of breakup fees if the deal fails. The potential for rule rollback with a new Congress and historical examples like the AbbVie-Shire deal are explored. Finally, it considers Allergan's future as an independent company, highlighting its financial stability and growth prospects.

How might changes in Congress affect the deal between Pfizer and Allergan?

What are the implications of the legacy Allergan portfolio's growth rate for the company's future?